Main Category: Regulatory Affairs / Drug Approvals
Also Included In: Pharmacy / Pharmacist
Article Date: 28 Oct 2012 – 2:00 PDT
Problems Identified At New England Compounding Center Facility, Says FDA
The New England Compounding Center (NECC) facility has problems maintaining its clean rooms, the Food and Drug Administration (FDA) informed as it released a copy of the FDA Form 483 to the NECC.
The FDA states it listed a number of “observations”, including contaminated products.
FDA inspectors visited NECC for a total of seven days from October 1st to 26th after the company had recalled a steroid medication.
The clean room is an enclosed space that is supposed to contain a controlled environment with minimum levels of airborne particles and surface contaminants. When sterile drug products are produced, it has to be done in an extremely clean room so that there is no microbial contamination during processing. Processing in the clean room goes all the way to filling the drug into its final container.
The Agency states it found mold inside the NECC, which was visible to the naked eye. Inspectors found 83 vials from one lot of the contaminated steroid that contained “greenish black foreign matter.”
In a bin of 321 vials of methylprednisolone acetate, inspectors found white fibers floating in them. Some vials from this lot had already been sent out to health care providers throughout the USA.
After the FDA carries out an inspection, and the investigators believe that conditions and practices might violate the Federal Food, Drug and Cosmetic Act, or related regulations, it issues a FDA Form 483.
The FDA emphasizes that the 483, in itself, is not an FDA conclusion that anything that is listed in the document is a violation of the Act or any related regulations.
After the 483 has been released, the FDA:
Considers the observations in the 483
Considers an Establishment Inspection Report (EIR) which the FDA investigators have prepared
Considers responses received from the company
Considers any other relevant informationThe FDA added that the inspectors have not yet finished the Establishment Inspection Report, and none of its contents are being shared for the moment.
After taking everything into consideration, the FDA decides whether or not to take any further action.
Several public health authorities are liaising closely regarding this matter, including the FDA, CDC (Centers for Disease Control and Prevention), say partners, and the Massachusetts Board of Registration in Pharmacy.
Background information – Outbreak of fungal meningitisIn the USA at the moment, there is an outbreak of fungal meningitis among patients who took NECC’s compounded preservative-free injectable steroid methylprednisolone acetate (80mg/ml).
A total of 338 people who were administered the contaminated steroid used for the treatment of back pain became infected with fungal meningitis, 25 have lost their lives so far. All the tainted products came from NECC.
Reuters quoted one NECC sales representative who stated “I remember thinking, are we just selling too much? Were we growing sales faster than our lab could handle?”
According to accounts by former NECC staff, customers and local press reports, the company grew rapidly, and appears to have taken shortcuts and breached regulations governing compounding practices virtually from day 1. Regulators are being accused of not punishing NECC despite repeated violations of regulations.
On Friday, NECC released the following statement:
“We will review this report and will continue our cooperation with the FDA. We will follow the existing regulatory process and provide our comments to the FDA after we have had adequate time for a complete review of the report.”
Massachusetts Governor, Deval Patrick announced that say authorities will, as from now, carry out annual unannounced inspections of the more than 25 other compounding pharmacies in the say that prepare sterile injectable drugs.
Not to be reproduced without permission of Medical News Today
Visit our regulatory affairs / drug approvals section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:
n.p. “Problems Identified At New England Compounding Center Facility, Says FDA.” Medical News Today. MediLexicon, Intl., 28 Oct. 2012. Web.
Please note: If no author information is provided, the source is cited instead.
Visitor Opinions (latest shown first)
Add Your Opinion On This Article’Problems Identified At New England Compounding Center Facility, Says FDA’
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
- HIV Rates Reaching Epidemic Levels In Greece
- Ootent growth factor for blood stem cells identified
- Genetic Variants Identified For Parkinson’s Disease Risk
- Trauma switch identified: Mechanism protects our brains from turning stress and trauma into post-traumatic stress disorder
- Delirium, an Adverse Outcome Faced by People With Alzheimer’s
- Pediatric treatment regime for ALL patients improves chances of long-term survival
- Tobacco cessation must be included as part of standard clinical care for cancer patients
- Mutations In JAK3 Gene Identified In Subtype Of Lymphoma Provide Potential Drug Target
- Like curry? New biological role identified for compound used in ancient medicine
- Protective Blood Factors Against Type 2 Diabetes Identified
Submited at Monday, October 29th, 2012 at 12:15 am on Uncategorized by samantha
Comment RSS 2.0 - leave a comment - trackback